BioTheranostics
Hologic Reports Gains in Non-COVID Diagnostics, Surgical Products
Company beats its Q3 earnings guidance on strength of women's health diagnostics income, and CEO Steve MacMillan predicted relief from chip supply problems
Hologic Preliminary Fiscal Q1 Revenues Drop 9 Percent
The firm expects fiscal Q1 Diagnostics revenues of $950.4 million, down 16 percent compared to the prior-year quarter when its COVID-19 revenues surged.
Medicare Expands Coverage for Hologic's Biotheranostics Breast Cancer Test
The firm said that the expanded coverage provides more women with access to a test that helps determine whether extended endocrine therapy is appropriate.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.